GET DAILY SIGNALSSTERIS (STE) Delivers Solid Q2 Beat and Raises Full-Year Guidance
Key Takeaways
- STERIS reported adjusted earnings per share (EPS) of $2.94 for its fiscal 2027 second quarter, beating the consensus estimate of $2.68 by roughly 9.8%.
- Revenue reached $1.59 billion, ahead of the $1.56 billion consensus and up about 8.8% from the same period a year earlier.
- Life Sciences was the standout, with capital equipment revenue surging 53% and segment revenue rising nearly 18% year over year.
- Management raised full-year adjusted EPS guidance to $11.35–$11.55, up from a prior range of $11.10–$11.30.
- Applied Sterilization Technologies capital equipment revenue declined 21%, and its full-year organic growth outlook was trimmed.
Earnings Context and Why It Matters
STERIS plc is a global provider of infection-prevention products and services, operating across Healthcare, Life Sciences, and Applied Sterilization Technologies segments. Its quarterly results serve as a barometer for hospital procedure volumes, medical-device manufacturing activity, and biopharmaceutical demand. The fiscal 2027 second quarter, which ended September 30, 2026, follows a fiscal first quarter in which the company posted adjusted EPS of $2.59 on revenue of $1.49 billion. With analysts focused on segment-level momentum and margin durability, this report carried added weight because it reveals whether strength in capital equipment and services could support a raised full-year outlook amid ongoing tariff costs and trade-policy uncertainty. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
What the Numbers Show
STERIS reported adjusted diluted EPS of $2.94 for the fiscal 2027 second quarter, exceeding the consensus estimate of $2.68 by approximately 9.8% and rising from $2.47 in the year-ago quarter. Revenue came in at $1.59 billion, above the $1.56 billion consensus and up about 8.8% year over year.
By segment, Healthcare revenue grew 8.6% to $1.12 billion, with both service and consumables each up 10%. Life Sciences revenue increased nearly 18% to $170.6 million, driven by a 53% jump in capital equipment revenue. Offsetting this, Applied Sterilization Technologies capital equipment revenue fell 21%.
Management raised its full-year adjusted EPS guidance to $11.35–$11.55 from $11.10–$11.30, while keeping consolidated revenue growth guidance unchanged at 7–8%. The company noted that roughly $0.18 of the guidance midpoint increase reflects tariff refunds related to levies previously paid under the International Emergency Economic Powers Act.
Market Reaction and Investor Sentiment
STERIS released its fiscal 2027 second-quarter results after the U.S. market close on November 4, 2026, with its conference call scheduled for the following morning. As a result, the full market reaction will unfold in subsequent trading sessions. STERIS has beaten consensus EPS estimates in five of its last eight quarters, a track record that has historically supported steady investor confidence in the name. The combination of a double-digit EPS beat, better-than-expected revenue, and a raised full-year outlook is likely to frame sentiment positively heading into the earnings call, though investors will also weigh the softer Applied Sterilization Technologies results and the one-time nature of the tariff refunds embedded in the guidance increase.
Forward Outlook and Key Factors to Monitor
STERIS enters the second half of fiscal 2027 with an upgraded earnings outlook, but several factors will shape how investors assess the path ahead.
First, the quality of the guidance raise matters. About $0.18 of the midpoint increase stems from tariff refunds tied to the International Emergency Economic Powers Act, meaning the underlying operational raise is smaller than the headline figures suggest. Management also flagged gross tariff costs of roughly $15 million per quarter and ongoing trade-policy uncertainty as persistent headwinds.
Second, segment momentum bears watching. Life Sciences full-year organic growth expectations were lifted to 9–10% from 6–7%, but the segment's backlog declined to $93.4 million from $113.7 million, a signal investors should track as it reflects how quickly the capital equipment surge draws down future order coverage.
Third, Applied Sterilization Technologies remains a soft spot, with capital equipment revenue down 21% and its full-year organic growth outlook trimmed to 6–7% from 7–8%.
Finally, the company noted a proposed acquisition of Xodus Medical, with a revised full-year outlook incorporating that deal expected after closing. Progress on that transaction, along with demand trends in hospital procedures and biopharmaceutical capital spending, will be key areas of focus in the quarters ahead. From what I see, this is important because it could influence near-term sentiment.
Integrating AI Tools into My Analysis
I often turn to Tickeron’s AI Screener when evaluating companies like STERIS to quickly filter for peers with similar fundamentals and technical setups. It helps me spot patterns and compare performance across the healthcare sector without spending hours on manual screens, giving me a clearer view of where the stock stands relative to the broader market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
STE in upward trend: price rose above 50-day moving average on October 15, 2026
STE moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend. In 27 of 43 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 63%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on STE as a result. In 44 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 46%.
The 10-day moving average for STE crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.
Following a +1.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where STE advanced for three days, in 153 of 312 cases, the price rose further within the following month. The odds of a continued upward trend are 49%.
The Aroon Indicator entered an Uptrend today. In 98 of 200 cases where STE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 49%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.
STE broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. STE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 66 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.130) is normal, around the industry mean (4.338). P/E Ratio (28.145) is within average values for comparable stocks, (1.324). Projected Growth (PEG Ratio) (1.760) is also within normal values, averaging (11.253). Dividend Yield (0.012) settles around the average of (0.010) among similar stocks. P/S Ratio (3.423) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 75 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of surgical and other medical supplies
Industry MedicalNursingServices
Advertisement